![Stacey L. Jurchison](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Stacey L.
Jurchison worked as a Communications Director & Head-Investor Relations at PharmAthene, Inc. from 2012 to 2014.
She also worked as a Senior Director-Investor Relations at Aptevo Therapeutics, Inc. and Altimmune, Inc. Additionally, she worked as an Executive Director-Corporate Affairs at Prelude Therapeutics, Inc. from 2019 to 2022.
Furthermore, she worked as an Investor Relations Contact & Head-Communications at Rexahn Pharmaceuticals, Inc.
Anciens postes connus de Stacey L. Jurchison
Sociétés | Poste | Fin |
---|---|---|
PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | - |
ALTIMMUNE, INC. | Investor Relations Contact | - |
REXAHN PHARMACEUTICALS, INC. | Investor Relations Contact | - |
APTEVO THERAPEUTICS INC. | Investor Relations Contact | - |
PharmAthene, Inc.
![]() PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
APTEVO THERAPEUTICS INC. | Health Technology |
ALTIMMUNE, INC. | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
Entreprise privées | 2 |
---|---|
PharmAthene, Inc.
![]() PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Health Technology |
Rexahn Pharmaceuticals, Inc.
![]() Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |